Next Science Ltd
ASX:NXS
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.125
0.47
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Next Science Ltd
Current Portion of Long-Term Debt
Next Science Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Next Science Ltd
ASX:NXS
|
Current Portion of Long-Term Debt
$274.8k
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Nanosonics Ltd
ASX:NAN
|
Current Portion of Long-Term Debt
AU$3.1m
|
CAGR 3-Years
29%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
||
Polynovo Ltd
ASX:PNV
|
Current Portion of Long-Term Debt
AU$1.7m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
SDI Ltd
ASX:SDI
|
Current Portion of Long-Term Debt
AU$657k
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-18%
|
||
Anteris Technologies Ltd
ASX:AVR
|
Current Portion of Long-Term Debt
AU$978k
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Ansell Ltd
ASX:ANN
|
Current Portion of Long-Term Debt
$77.5m
|
CAGR 3-Years
55%
|
CAGR 5-Years
31%
|
CAGR 10-Years
18%
|
Next Science Ltd
Glance View
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
See Also
What is Next Science Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
274.8k
USD
Based on the financial report for Dec 31, 2023, Next Science Ltd's Current Portion of Long-Term Debt amounts to 274.8k USD.
What is Next Science Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
17%
Over the last year, the Current Portion of Long-Term Debt growth was 7%. The average annual Current Portion of Long-Term Debt growth rates for Next Science Ltd have been 17% over the past three years .